Reduced-folate carrier (RFC) is expressed in placenta and yolk sac, as well as in cells of the developing forebrain, hindbrain, neural tube, craniofacial region, eye, limb buds and heart by unknown
BioMed CentralBMC Developmental Biology
ssOpen AcceResearch article
Reduced-folate carrier (RFC) is expressed in placenta and yolk sac, 
as well as in cells of the developing forebrain, hindbrain, neural tube, 
craniofacial region, eye, limb buds and heart
Dennis M Maddox1, Anna Manlapat1, Penny Roon1, Puttur Prasad2, 
Vadivel Ganapathy3 and Sylvia B Smith*1,4
Address: 1Department of Cellular Biology and Anatomy, Medical College of Georgia, Augusta, USA, 2Department of Obstetrics and Gynecology, 
Medical College of Georgia, Augusta, USA, 3Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta, USA and 
4Department of Ophthalmology, Medical College of Georgia, Augusta, USA
Email: Dennis M Maddox - oxmandm@yahoo.com; Anna Manlapat - amanlapat@mail.mcg.edu; Penny Roon - proon@mail.mcg.edu; 
Puttur Prasad - pprasad@mail.mcg.edu; Vadivel Ganapathy - vganapat@mail.mcg.edu; Sylvia B Smith* - sbsmith@mail.mcg.edu
* Corresponding author    
Abstract
Background: Folate is essential for cellular proliferation and tissue regeneration. As mammalian
cells cannot synthesize folates de novo, tightly regulated cellular uptake processes have evolved to
sustain sufficient levels of intracellular tetrahydrofolate cofactors to support biosynthesis of
purines, pyrimidines, and some amino acids (serine, methionine). Though reduced-folate carrier
(RFC) is one of the major proteins mediating folate transport, knowledge of the developmental
expression of RFC is lacking. We utilized in situ hybridization and immunolocalization to determine
the developmental distribution of RFC message and protein, respectively.
Results: In the mouse, RFC transcripts and protein are expressed in the E10.0 placenta and yolk
sac. In the E9.0 to E11.5 mouse embryo RFC is widely detectable, with intense signal localized to
cell populations in the neural tube, craniofacial region, limb buds and heart. During early
development, RFC is expressed throughout the eye, but by E12.5, RFC protein becomes localized
to the retinal pigment epithelium (RPE).
Conclusions: Clinical studies show a statistical decrease in the number of neural tube defects,
craniofacial abnormalities, cardiovascular defects and limb abnormalities detected in offspring of
female patients given supplementary folate during pregnancy. The mechanism, however, by which
folate supplementation ameliorates the occurrence of developmental defects is unclear. The
present work demonstrates that RFC is present in placenta and yolk sac and provides the first
evidence that it is expressed in the neural tube, craniofacial region, limb buds and heart during
organogenesis. These findings suggest that rapidly dividing cells in the developing neural tube,
craniofacial region, limb buds and heart may be particularly susceptible to folate deficiency.
Background
Folates are highly lipophobic, bivalent anions that can
only minimally traverse biological membranes by simple
diffusion [1]. Because they pass so inefficiently through
biological membranes, supply of folates through mam-
malian cell plasma membranes must occur by a mediated
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known as RFC-1, FOLT, RFT-1 or SLC19A1) (Mr 60 kDa)
is a typical transport protein with 12 membrane-spanning
domains. RFC preferentially transports reduced folates,
such as N5-methytetrahydrofolate (MTF), the most com-
mon form of circulating folate. In adult tissues, RFC is
expressed in the brush-border membrane of jejunum,
ileum, duodenum and colon and in the basolateral mem-
brane of renal tubular epithelium, hepatocytes, choroid
plexus [2] and the retinal pigment epithelium (RPE) of
the eye [3].
The importance of RFC during embryogenesis has been
demonstrated by the use of targeted gene deletion. Mice
with targeted deletions of RFC die at an early embryonic
age [4]. Thus, although it is evident the RFC is needed for
normal embryonic development, the tissue-specific
requirements for RFC during embryogenesis remain
largely a mystery. In the present study we offer the first
developmental analysis of the embryonic tissue Distribu-
tion of RFC message and protein in mouse placenta and
developing embryo.
Results
Expression of RFC mRNA and protein in E10.0 mouse 
uterine sections
In situ hybridization analysis was performed on cryosec-
tions of mouse uterus obtained at embryonic day (E)10.0
of gestation. Figure 1A shows that RFC message is
expressed in trophoblast cells of all layers of the placenta,
with the expression most abundant in the trophoblast
cells surrounding blood lacunae. RFC message was
expressed also in the trophoblastic giant cells, labyrinth,
junctional zone, yolk sac and within the neural tube of the
developing embryo (Figure 1A and 1C). Specificity of the
staining was verified by hybridization of placental sec-
tions with an RFC specific sense probe as a negative con-
trol (Figure 1E). The presence of RFC protein in mouse
placenta was determined by immunofluorescence using
frozen sections of E10.0 day mouse placenta. RFC-specific
antibody [3] produced immune reaction in trophoblast
cells of all layers of the mouse placenta (Figure 1B). RFC
message was detected abundantly in the trophoblast cells
surrounding blood lacunae in the labyrinth zone.
Immunofluorescence showed that RFC protein was
present widely throughout the placenta with particularly
intense expression in the trophoblastic giant cells, the
yolk sac and within the neural tube of the developing
embryo (Figure 1B and 1D). Specificity of the RFC anti-
body was confirmed by the lack of fluorescence in tissues
incubated with RFC antibody previously treated with
blocking peptide (Figure 1F).
Expression of mRNA encoding RFC in whole-mount 
embryos from E9.0 to E11.5
Further analysis of RFC mRNA expression was carried out
utilizing mouse embryos ranging from E9.0 to E11.5 (Fig-
ure 2). Three or more embryos were examined for each
time point. RFC message was detectable in all tissues
throughout the embryos, with the most intense levels of
expression being confined to the forebrain, hindbrain,
craniofacial region, eye (optic vesicles), mandible, heart,
somites, and tail (Figure 2A). In E10.5 (Figure 2B) and
E11.5 (Figure 2C) embryos, expression in the forebrain,
hindbrain, craniofacial region, eye (optic vesicles), man-
dible, heart, somites, and tail were maintained, while
additional expression became detectable in the develop-
ing limb buds. Faint signal was also visible in the yolk sac
(data not shown). Negative control experiments with
sense riboprobes for RFC resulted in minimal background
staining (Figure 2D).
Immunohistochemical detection of RFC protein at E9.0 
through E10.5
The distribution pattern of RFC protein in E9.0 through
E10.5 ICR mouse embryos was determined by whole-
mount immunohistochemical localization. Positive sig-
nal was ubiquitously present, but at E9.0 the signal was
most intense in the optic vesicles, forebrain, mandible,
heart, somites and tail bud (Figure 3A). At E9.5 RFC pro-
tein was detectable in the developing limb buds (Figure
3B) and by E10.5, besides being present in the developing
eye, forebrain, hindbrain, somites, mandible, heart and
limb buds, RFC was detectable also in the neural tube and
nasal pits (Figure 3C). Control experiments in which tis-
sues were incubated with pre-blocked primary antibody
exhibited little background staining (Figure 3D).
In addition to localizing RFC in numerous tissues of the
developing embryo as shown in figure 3, we were particu-
larly interested in its localization in the developing eye.
Our laboratory has evaluated this protein in adult retina
[3,5]. As shown in figure 4A RFC was present throughout
the developing lens and retina at E10. As development
continues through E12.5, RFC signal becomes undetecta-
ble in the lens, while signal in the retina becomes con-
fined to the retinal pigment epithelium (RPE) (Figure 4B).
Expression appeared to be greater in the dorsal RPE as
compared to the ventral RPE (Figure 4B). Control experi-
ments performed with either fluorescent secondary anti-
body (Figure 4C) or horse-radish peroxidase conjugated
secondary antibody (Figure 4D) gave little background.
Discussion
In trans-uterine sections of E10.0 pregnant mouse uterus,
we found that RFC mRNA and protein were widely dis-
tributed throughout the placenta. While studies by Wang
et al. [2] suggested that RFC expression in adult tissues isPage 2 of 8
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BMC Developmental Biology 2003, 3 http://www.biomedcentral.com/1471-213X/3/6In situ hybridization and immunolocalization of RFC during early murine embryonic developmentFigure 1
In situ hybridization and immunolocalization of RFC during early murine embryonic development. Panels A and 
C demonstrate expression of RFC mRNA in a section of uterus containing an E10.0 embryo. Panel E demonstrates the absence 
of background staining when a sense riboprobe for RFC is hybridized with placental sections as a negative control. To deter-
mine whether RFC protein may be localized to the same areas that are positive for RFC message during murine embryonic 
development, immunofluorescence was utilized in E10.0 frozen uterus sections. Panels B and D indeed verify that RFC protein 
is localized in a manner consistent with the expression pattern of RFC message. Specificity of the RFC antibody is demon-
strated by lack of fluorescence in tissues incubated with RFC antibody that had been pre-incubated with blocking peptide 
(Panel F). L, labyrinth zone; NT, neural tube; JZ, junctional zone; TG, trophoblastic giant cells; YS, yolk sac. Scale bar represents 
25 µm in A and E and 4 µm in B, C and D.Page 3 of 8
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membrane of the jejunum, ileum, duodenum, and colon
or the basolateral membranes of renal tubular epithelium,
hepatocytes and choroid plexus, more recent studies sug-
gest a more ubiquitous expression in adult tissues [6]. In
accordance with these recent findings, in situ hybridiza-
tion and immunolocalization analysis of whole-mount
embryos revealed that RFC mRNA and protein were
Analysis of RFC mRNA transcripts in E9.5-E11.5 mouse embryosFigure 2
Analysis of RFC mRNA transcripts in E9.5-E11.5 mouse embryos. RFC mRNA was widely expressed; however, struc-
tures undergoing developmental changes requiring rapid cell division expressed the mRNAs most strongly. Panels A-C demon-
strate expression of RFC mRNA in embryos varying in age from E9.5 to E11.5. Light purple staining indicates the widespread 
nature of the RFC message. Regions of more intense staining include the forebrain, eye, hindbrain, mandible, heart, limb buds, 
somites, tail and yolk sac. Panel D depicts a control in situ hybridization performed with RFC sense riboprobes. Lack of back-
ground staining verifies that the signal in the experimental specimens is specific. Forebrain, FB; eye, E; hindbrain, HB; mandible, 
M; heart, H; limb buds, LB; somites, S; tail, T. Scale bar represents 50 µm.Page 4 of 8
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optic vesicles, forebrain, mandible, heart, somites and tail
bud. By E10.5 RFC was also detectable in the neural tube,
limb buds and nasal pits. In the eye RFC mRNA and pro-
tein were expressed ubiquitously through E12.0. By E12.5,
However, the RFC protein was no longer present through-
out the developing eye; instead it had segregated to the
apical plasma membrane of the RPE, its adult location in
the eye [3].
Immunohistochemical detection of RFC in developing mouse embryosFigure 3
Immunohistochemical detection of RFC in developing mouse embryos. Panels A and B demonstrate staining for 
RFC in an E9.0 and E9.5 embryo, respectively. Positive signal is detected throughout the embryo, with the signal being more 
intense in the optic vesicles, mandible, heart, somites, limb buds and tail bud. At E10.5 (panel C) expression of RFC is present 
in the aforementioned tissues as well as in the neural tube, nasal pits and developing eye. Control embryos incubated with pre-
blocked antibody demonstrated no signal (Panel D). optic vesicle, OV; mandible, M; heart, H; somites, S; limb buds, LB; tail bud, 
TB; neural tube, NT; nasal pits, NP; developing eye, DE. Scale bar represents 50 µm in A, C, E and F and 100 µm in B and D.Page 5 of 8
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the mechanism by which the beneficial effects of folate
supplementation during pregnancy are derived. Many
studies have shown a statistically significant decrease in
Immunofluorescent and immunohistochemical detection of RFC in developing mouse eyeFigure 4
Immunofluorescent and immunohistochemical detection of RFC in developing mouse eye. Panel A demonstrates 
immunofluorescent signal for RFC present throughout the developing retina and lens of an E10.0 ICR mouse embryo. As devel-
opment continues through E12.5, signal in the lens diminishes, while the signal in the retina becomes confined to the RPE (Panel 
B). Expression appears to be greater in the dorsal region of the retina (black arrow). Sections incubated with pre-blocked anti-
body demonstrated no signal (Panels C and D). R, retina; L, lens. Scale bar represents 10 µm.Page 6 of 8
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spring of female patients who were given supplemental
vitamins containing folate during pregnancy [7–9]. To a
lesser extent, folate supplementation has also been shown
to decrease the incidence of craniofacial abnormalities
[10–12], cardiovascular defects [13,14] and limb
abnormalities [15] in humans. This work demonstrates
that RFC mRNA and protein are present in rapidly divid-
ing cell populations of the mouse embryo during early
organogenesis of these structures.
Conclusions
The pattern of RFC mRNA and protein expression is devel-
opmentally regulated. While RFC expression is most
strongly present in specialized cell-types in adult mice,
during development RFC mRNA and protein are
expressed in the placenta, yolk sac and throughout the
embryo, with higher levels of expression being confined
to cell populations in the neural tube, forebrain, hind-
brain, craniofacial region, eye, limb buds, heart, somites
and tail. Mutations in the RFC gene or deficient maternal
folate intake may lead to developmental defects by
decreasing proliferation rates in the cell populations




ICR male and female mice were purchased from Harlan
Sprague Dawley (Indianapolis, IN). Timed pregnancies
were obtained by checking mating plugs and the morning
a plug was detected was defined as E0.5. Pregnant female
ICR mice were sacrificed by cervical dislocation, the uter-
ine horns opened immediately and the embryos collected
in cold diethyl pyrocarbonate (DEPC)-treated (0.01 M)
PBS. Care and use of mice adhered to the principles set
forth in DHEW Publication NIH 80–23 (Guiding Princi-
ples in the care and use of animals).
Whole-mount in situ hybridization
The sense and antisense digoxigenin (DIG)-labeled cRNA
probes for mouse RFC transcripts were prepared using a
DIG RNA labeling kit (Boehringer Mannheim, Indianap-
olis, IN) following the manufacturer's protocol. The
cDNA used to generate cRNA probes was obtained by
reverse transcriptase polymerase chain reaction (RTPCR)
performed on total eye RNA using the primers 5'-AGCGA-
TAAGCCTACAGGATGG-AGACCTA-3' (sense) and 5'-
CTGCAGGCTCAGCGGACCTTGGCT-3' (antisense)
which amplified a 618-bp fragment between bases 1558
and 2175 of the published RFC sequence (Genbank acces-
sion number NM031196) [16]. The amplified product
was cloned into pGEM-T vector in an orientation produc-
ing sense probe by T7 RNA polymerase-mediated tran-
scription and antisense probe by SP6 RNA polymerase-
mediated transcription. The identity of the amplified
products was confirmed by nucleotide sequencing and in
situ hybridization was performed as previously described
[17]. Specimen were photographed without clearing using
a Zeiss Axioskop microscope or a Zeiss Stemi-2000 C dis-
secting scope equipped with a Spot camera.
Immunohistochemistry
Immunohistochemistry on cryosections was performed as
previously described [3]. Whole embryos were processed
for immunohistochemistry by fixation in 4% PFA for 2 h
at 4°C followed by rinsing in PBS. Embryos were dehy-
drated through a graded ethanol series and the tissues
were re-fixed with methanol:dimethylsulfoxide (DMSO)
(4:1) overnight at room temperature followed by metha-
nol:DMSO:30% H2O2 (4:1:1) at room temperature for 4
h. Embryos were rehydrated through reverse ethanol
series. Nonspecific binding was blocked by incubating the
embryos in PBSTMD (2% skim milk powder, 1% DMSO
in PBS containing 0.1% Tween 20). The RFC-1 anti-pep-
tide antibody was raised against the peptide sequence
RPKRSLFFNRDDRGRC, corresponding to residues 205–
220 of human RFC-1 and was used at a 1:500 dilution
[3,18]. The specificity of this antibody has been described
[18]. Control experiments were carried out by incubating
the antibody with the RPKRSLFFNRDDRGRC peptide at a
concentration of 2 µg/ml for 30 minutes prior to begin-
ning the experiment. Incubations were carried out in
PBSTMD overnight at 4°C. The antibody solution was
removed and embryos were rinsed twice with PBS follow-
ing which they were washed 4 × 1 h in PBST. Embryos
were blocked with PBSTMD for 4 h, the secondary horse-
radish peroxidase (HRP)-conjugated antibodies were
added in PBSTMD (1:100) and the embryos were incu-
bated overnight at 4°C. Embryos were rinsed 2× with PBS
and washed for 4 × 1 h in PBST before being incubated for
1 h in 500 µl DAB solution (1 mg/ml in PBST). 500 µl of
0.03% H2O2 was added and 3–5 minutes were allowed for
the color to develop before the embryos were rinsed in
PBS and photographed using a Zeiss Axioskop microscope
equipped with a Spot camera.
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